

Challenges in diagnosing mesenteric ischemia

Teun C van den Heijkant, Bart AC Aerts, Joep A Teijink, Wim A Buurman, Misha DP Luyer

Teun C van den Heijkant, Joep A Teijink, Misha DP Luyer, Department of Surgery, Catharina Hospital Eindhoven, 5623 EJ Eindhoven, The Netherlands

Bart AC Aerts, Department of Surgery, Amphia Hospital, 4818 CK Breda, The Netherlands

Wim A Buurman, Institute Nutrim, Maastricht University, 6200 MD Maastricht, The Netherlands

Author contributions: van den Heijkant TC and Aerts BAC drafted the manuscript; Teijink JA, Buurman WA and Luyer MDP authored the manuscript; all authors read, edited and approved the final manuscript.

Correspondence to: Misha DP Luyer, MD, PhD, Department of Surgery, Catharina Hospital Eindhoven, 5623 EJ Eindhoven, The Netherlands. misha.luyer@cze.nl

Telephone: +31-40-2399111 Fax: +31-40-2455035

Received: May 9, 2012 Revised: September 30, 2012

Accepted: October 16, 2012

Published online: March 7, 2013

Abstract

Early identification of acute mesenteric ischemia (AMI) is challenging. The wide variability in clinical presentation challenges providers to make an early accurate diagnosis. Despite major diagnostic and treatment advances over the past decades, mortality remains high. Arterial embolus and superior mesenteric artery thrombosis are common causes of AMI. Non-occlusive causes are less common, but vasculitis may be important, especially in younger people. Because of the unclear clinical presentation and non-specific laboratory findings, low clinical suspicion may lead to loss of valuable time. During this diagnostic delay, progression of ischemia to transmural bowel infarction with peritonitis and septicemia may further worsen patient outcomes. Several diagnostic modalities are used to assess possible AMI. Multi-detector row computed tomographic angiography is the current gold standard. Although computed tomographic angiography leads to an accurate diagnosis in many cases, early detection is a persistent problem. Because early diagnosis is vital to commence treatment, new diagnostic strategies are needed. A non-invasive simple biochemical test would

be ideal to increase clinical suspicion of AMI and would improve patient selection for radiographic evaluation. Thus, AMI could be diagnosed earlier with follow-up computed tomographic angiography or high spatial magnetic resonance imaging. Experimental *in vitro* and *in vivo* studies show promise for alpha glutathione S transferase and intestinal fatty acid binding protein as markers for AMI. Future research must confirm the clinical utility of these biochemical markers in the diagnosis of mesenteric ischemia.

© 2013 Baishideng. All rights reserved.

Key words: Acute mesenteric ischemia; Diagnosis; Biological markers; Intestinal fatty acid binding protein; Alpha-glutathione S transferase

van den Heijkant TC, Aerts BAC, Teijink JA, Buurman WA, Luyer MDP. Challenges in diagnosing mesenteric ischemia. *World J Gastroenterol* 2013; 19(9): 1338-1341 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v19/i9/1338.htm> DOI: <http://dx.doi.org/10.3748/wjg.v19.i9.1338>

INTRODUCTION

Mesenteric ischemia accounts for approximately 1% of acute abdomen hospitalizations and occurs in one in 1000 patients presenting to emergency rooms^[1,2]. Despite growing recognition of this entity and interest in preventing irreversible ischemia, identification and early diagnosis is challenging because early symptoms are non-specific^[3]. Despite major diagnostic and treatment advances over the past decades, low clinical suspicion leads to persistently high mortality rates of 40% to 70% for acute mesenteric ischemia (AMI)^[4]. Early diagnosis is necessary to commence appropriate treatment, whereas diagnostic delay contributes to poor patient outcomes. A 24-h delay decreases survival rates by 20%^[5]. Therefore, development of new diagnostic strategies is of great importance. Ideally, a highly specific and sensitive, non-invasive marker is needed to identify patients earlier.

MESENTERIC ISCHEMIA

Etiology and clinical presentation

In 70% to 80% of cases, intestinal ischemia is caused by an arterial embolus or thrombosis within the superior mesenteric artery. In cases of embolic occlusion, the absence of a well-developed collateral circulation causes earlier ischemia and transmural necrosis compared with other causes of mesenteric ischemia. Less common causes are venous thrombosis and non-thrombotic mechanical causes such as strangulated hernia. Patients with a history of arterial emboli, vasculitis, deep venous thrombosis, hypercoagulable state, or chronic postprandial pain are at increased risk. Vasculitis is a common cause of mesenteric ischemia in younger people with auto-immune disease. Finally, case reports implicate vascular anomalies as a cause of mesenteric ischemia.

There are a wide variety of clinical presentations for mesenteric ischemic. Classically, AMI is associated with a dramatic onset of severe abdominal pain disproportionate to the physical exam. Pain develops once the ischemia has progressed transmurally. Postprandial pain, nausea and weight loss often occur in patients with chronic mesenteric ischemia and superior mesenteric artery thrombosis. In chronic mesenteric ischemia, the association of pain with meals leads to fear of eating and subsequent weight loss.

Early diagnosis is challenging because of the wide variability in clinical presentation of mesenteric ischemia.

Imaging techniques

Classically, patients with mesenteric ischemia have leukocytosis, metabolic acidosis, an elevated D-dimer and elevated serum lactate. Although profound leukocytosis with peripheral white blood cell counts exceeding $20 \times 10^9/L$ have been reported, this finding is not useful to distinguish AMI from other diagnoses. In a prospective clinical trial, Acosta *et al*^[13] investigated the classically described metabolic acidosis. In their study, initial blood gas analysis showed metabolic alkalosis more frequently than metabolic acidosis; this finding results from patients found vomiting during early bowel ischemia. D-dimer is also purported as an important tool in diagnosing AMI. However, D-dimer, an enzymatic degradation product of fibrin, is also elevated in a wide variety of conditions, as several other conditions.^[14] A recent trial demonstrated that serum D-dimer detection does not differentiate patients with AMI from those with non-acute mesenteric ischemia, and that there is no difference in serum D-dimer levels between resectable and unresectable bowel necrosis lesions.^[15] L-lactate is associated with late-stage mesenteric ischemia with extensive transmural intestinal infarction, body tissue hypoperfusion, anaerobic metabolism, and death.^[16] Some studies report absence of systemic plasma L-lactate elevation in cases of extensive intestinal ischemia. This absence of L-lactate is probably explained by the liver's capacity to clear large quantities of L-lactate from the porto-mesenteric circulation.^[17]

Marker	Sensitivity	Specificity	Positive likelihood-ratio (95%CI)	Negative likelihood-ratio (95%CI)
WBC count ¹	0.80	0.50	1.57 (1.07, 2.27)	0.41 (0.20, 0.83)
pH ¹	0.38	0.84	2.49 (0.82, 7.51)	0.71 (0.45, 1.14)
D-dimer ¹	0.89	0.40	1.48 (1.28, 1.71)	0.30 (0.14, 0.64)

Evennett *et al*^[19]. WBC: White blood cell.

Thuijls *et al*^[18] confirmed that plasma L-lactate level, base excess and leukocyte count cannot be used as markers in patients suspected of having intestinal ischemia. They provided blood and urine samples. Plasma L-lactate level, base excess and leukocyte count were nondiscriminatory in determining whether patients had intestinal ischemia or other disease such as stomach perforation, pancreatitis or perforated appendicitis. Leukocyte counts in that study were significantly elevated in the mesenteric ischemia group versus the control group.

Table 1 shows that classically described laboratory markers have insufficient likelihood ratios. These laboratory markers usually occur only after transmural bowel infarction, and therefore, cannot be used for early diagnosis.

Imaging techniques

The American Gastroenterological Association guideline (2000) states that mesenteric angiography is the gold standard for the diagnosis of mesenteric ischemia. When the clinician is aware of possible AMI, angiography is accurate and increases survival. However, catheter angiography is invasive and time consuming. Furthermore, the unavailability of this diagnostic modality at most hospitals leads to a critical delay. At the time of the 2000 guideline, computed tomography (CT)-angiography (CTA) seemed promising, but there was limited experience with this modality then. Over the last decade, however, there has been a major shift toward CTA because it is less invasive, less time- and resource-consuming, and more readily available. Today, CTA has replaced angiography as the gold standard in diagnosing mesenteric ischemia with a sensitivity and specificity similar to that of angiography.^[21,22] These sensitivities are questionable because it is unlikely whether all AMI characteristics are evaluated by specialized radiologists at all practice locations.

Wiesner *et al*^[23] described a group of 291 patients who presented with acute abdomen and underwent multidetector-row computed tomographic scans. All original computed tomographic diagnoses were made

during several radiologists' daily routines. The sensitivity and specificity of multidetector-row CTA for the diagnosis of AMI were 0.79 and 0.98, respectively. These statistical measures may better reflect daily practice. In these cases, no focused structural radiological search was performed. There were different examination protocols because of suspected diagnosis. Arterial phase scanning was not performed regularly if there was no specific indication. Based on the current evidence, CTA is acceptable and accurate in diagnosing AMI; however, low bowel obstruction. I-FABP has been reported as a specific urinary I-FABP¹⁹¹. The rapid clearance of plasma FABPs (calculated half-life time of eleven minutes) plus urinary FABP accumulation following intestinal damage make urinary FABP more diagnostically useful compared to plasma FABP. These findings suggest (biochemical markers) or seek to optimize accurate diagnosis using existing modalities such as contrast-enhanced magnetic resonance angiography (CE-MRA). CE-MRA of the splanchnic vessels is an evolving technology which is theoretically appealing because it is non-invasive and avoids the nephrotoxicity and allergic risks associated with iodinated contrast agents. Dynamic CE-MRA of a range of toxic compounds within the cell by conjugation of LuFathone. Alpha-GST is known to be highly specific, in a clinical trial designed to diagnose severe stenosis or occlusion of the origins of the celiac axes and superior mesenteric artery. However, this modality is limited to identification of more distally located occlusions and does not have the same spatial resolution as CTA. If better spatial resolution becomes available in the future, CE-MRA has the potential to become the diagnostic modality of choice. A third suggested marker for AMI is D-lactate, which originates from bacteria such as *Escherichia coli* in the intestinal lumen¹⁹¹. It was hypothesized that lactate levels increase during mesenteric ischemia due to bacterial translocation and overgrowth following mucosal injury. However, a recent review showed a pooled sensitivity of 0.82 and 0.48, respectively. Therefore, D-lactate cannot be used as a marker for AMI, given the superiority of alternatives such as I-FABP and alpha-GST.

NEW DIAGNOSTIC STRATEGIES

biochemical markers) or seek to optimize accurate diagnosis using existing modalities such as contrast-enhanced magnetic resonance angiography (CE-MRA). CE-MRA of the splanchnic vessels is an evolving technology which is theoretically appealing because it is non-invasive and avoids the nephrotoxicity and allergic risks associated with iodinated contrast agents. Dynamic CE-MRA of a range of toxic compounds within the cell by conjugation of LuFathone. Alpha-GST is known to be highly specific, in a clinical trial designed to diagnose severe stenosis or occlusion of the origins of the celiac axes and superior mesenteric artery. However, this modality is limited to identification of more distally located occlusions and does not have the same spatial resolution as CTA. If better spatial resolution becomes available in the future, CE-MRA has the potential to become the diagnostic modality of choice. A third suggested marker for AMI is D-lactate, which originates from bacteria such as *Escherichia coli* in the intestinal lumen¹⁹¹. It was hypothesized that lactate levels increase during mesenteric ischemia due to bacterial translocation and overgrowth following mucosal injury. However, a recent review showed a pooled sensitivity of 0.82 and 0.48, respectively. Therefore, D-lactate cannot be used as a marker for AMI, given the superiority of alternatives such as I-FABP and alpha-GST.

Biochemical markers for early detection

In AMI, ischemia starts at the mucosa and extends toward the serosa. An ideal biomarker for mesenteric ischemia should originate at the mucosa to detect ischemia at the earliest stage. According to a recent review by Evennett et al¹⁹¹, intestinal fatty acid binding protein (I-FABP), alpha-glutathione S transferase (GST) and D-lactate are the most promising plasma markers for mesenteric ischemia. Fatty acid binding proteins comprise a class of low molecular weight (14-15 kDa) cytosolic proteins. I-FABP is a small cytosolic protein found in tissues involved in uptake and consumption of fatty acids. It is highly expressed in cells on the luminal side of small intestinal villi. I-FABP is released into the circulation and

CONCLUSION

AMI is a rare condition with a non-specific clinical presentation which makes early diagnosis challenging. Despite technical advances in imaging leading to more accurate diagnosis, AMI is often diagnosed late or even missed due to low clinical suspicion; therefore, a high mortality rate results. A readily available, simple, highly sensitive and specific marker to identify patients with AMI early would be of great importance in selecting candidates for CTA. Future research must confirm the clinical utility of promising biochemical markers such as I-FABP and GST.

REFERENCES

- 1 **Brandt L**, Boley S, Goldberg L, Mitsudo S, Berman A. Colitis in the elderly. A reappraisal. *Am J Gastroenterol* 1981; **76**: 239-245 [PMID: 7315820]
- 2 **Menke J**. Diagnostic accuracy of multidetector CT in acute mesenteric ischemia: systematic review and meta-analysis. *Radiology* 2010; **256**: 93-101 [PMID: 20574087 DOI: 10.1148/radiol.10091938]
- 3 **Oldenburg WA**, Lau LL, Rodenberg TJ, Edmonds HJ, Burger CD. Acute mesenteric ischemia: a clinical review. *Arch Intern Med* 2004; **164**: 1054-1062 [PMID: 15159262 DOI: 10.1001/archinte.164.10.1054]
- 4 **Kassahun WT**, Schulz T, Richter O, Hauss J. Unchanged high mortality rates from acute occlusive intestinal ischemia: six year review. *Langenbecks Arch Surg* 2008; **393**: 163-171 [PMID: 18172675 DOI: 10.1007/s00423-007-0263-5]
- 5 **Boley SJ**, Feinstein FR, Sammartano R, Brandt LJ, Sprayregen S. New concepts in the management of emboli of the superior mesenteric artery. *Surg Gynecol Obstet* 1981; **153**: 561-569 [PMID: 7280946]
- 6 **Sabiston DC**, Lyerly HK. Textbook of surgery: The biological basis of modern surgical practice. 15th ed. Pennsylvania: WB Saunders Company, 1997: 1752-1756
- 7 **Brandt LJ**, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. *Gastroenterology* 2000; **118**: 954-968 [PMID: 10784596 DOI: 10.1016/S0016-5085(00)70183-1]
- 8 **Hokama A**, Kishimoto K, Ihama Y, Kobashigawa C, Nakamoto M, Hirata T, Kinjo N, Higa F, Tateyama M, Kinjo F, Iseki K, Kato S, Fujita J. Endoscopic and radiographic features of gastrointestinal involvement in vasculitis. *World J Gastrointest Endosc* 2012; **4**: 50-56 [PMID: 22442741 DOI: 10.4253/wjge.v4.i3.50]
- 9 **Dutta U**, Bapuraj R, Yadav TD, Lal A, Singh K. Mesenteric ischemia and portal hypertension caused by splenic arteriovenous fistula. *Indian J Gastroenterol* 2004; **23**: 184-185 [PMID: 15599003]
- 10 **Kayacetin E**, Karakose S, Karabacakoglu A, Emlik D. Mesenteric ischemia: an unusual presentation of fistula between superior mesenteric artery and common hepatic artery. *World J Gastroenterol* 2004; **10**: 2605-2606 [PMID: 15300918]
- 11 **Block T**, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for intestinal ischaemia. *Scand J Clin Lab Invest* 2008; **68**: 242-248 [PMID: 17934974 DOI: 10.1080/00365510701646264]
- 12 **Sise MJ**. Mesenteric ischemia: the whole spectrum. *Scand J Surg* 2010; **99**: 106-110 [PMID: 20679047]
- 13 **Acosta S**, Björck M. Acute thrombo-embolic occlusion of the superior mesenteric artery: a prospective study in a well defined population. *Eur J Vasc Endovasc Surg* 2003; **26**: 179-183 [PMID: 12917835 DOI: 10.1053/ejvs.2002.1893]
- 14 **Schoots IG**, Levi MM, Reekers JA, Lameris JS, van Gulik TM. Thrombolytic therapy for acute superior mesenteric artery occlusion. *J Vasc Interv Radiol* 2005; **16**: 317-329 [PMID: 15758127 DOI: 10.1097/01.RVI.0000141719.24321.0B]
- 15 **Chiu YH**, Huang MK, How CK, Hsu TF, Chen JD, Chern CH, Yen DH, Huang CI. D-dimer in patients with suspected acute mesenteric ischemia. *Am J Emerg Med* 2009; **27**: 975-979 [PMID: 19857417 DOI: 10.1016/j.ajem.2009.06.006]
- 16 **Acosta S**, Nilsson T. Current status on plasma biomarkers for acute mesenteric ischemia. *J Thromb Thrombolysis* 2012; **33**: 355-361 [PMID: 22081293]
- 17 **Jakob SM**, Merasto-Minkkinen M, Tenhunen JJ, Heino A, Alhava E, Takala J. Prevention of systemic hyperlactatemia during splanchnic ischemia. *Shock* 2000; **14**: 123-127 [PMID: 10947154 DOI: 10.1097/00024382-200014020-00008]
- 18 **Thuijls G**, van Wijck K, Grootjans J, Derikx JP, van Bijnen AA, Heineman E, Dejong CH, Buurman WA, Poeze M. Early diagnosis of intestinal ischemia using urinary and plasma fatty acid binding proteins. *Ann Surg* 2011; **253**: 303-308 [PMID: 21245670 DOI: 10.1097/SLA.0b013e318207a767]
- 19 **Evennett NJ**, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. *World J Surg* 2009; **33**: 1374-1383 [PMID: 19424744 DOI: 10.1007/s00268-009-0074-7]
- 20 **Clark RA**, Gallant TE. Acute mesenteric ischemia: angiographic spectrum. *AJR Am J Roentgenol* 1984; **142**: 555-562 [PMID: 6141717]
- 21 **Kirkpatrick ID**, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. *Radiology* 2003; **229**: 91-98 [PMID: 12944600 DOI: 10.1148/radiol.2291020991]
- 22 **Wyers MC**. Acute mesenteric ischemia: diagnostic approach and surgical treatment. *Semin Vasc Surg* 2010; **23**: 9-20 [PMID: 20298945 DOI: 10.1053/j.semvasc.2009.12.002]
- 23 **Wiesner W**, Hauser A, Steinbrich W. Accuracy of multidetector row computed tomography for the diagnosis of acute bowel ischemia in a non-selected study population. *Eur Radiol* 2004; **14**: 2347-2356 [PMID: 15378337 DOI: 10.1007/s00330-004-2462-6]
- 24 **Meaney JF**, Prince MR, Nostrant TT, Stanley JC. Gadolinium-enhanced MR angiography of visceral arteries in patients with suspected chronic mesenteric ischemia. *J Magn Reson Imaging* 1997; **7**: 171-176 [PMID: 9039611 DOI: 10.1002/jmri.1880070126]
- 25 **Iacobellis F**, Berritto D, Somma F, Cavaliere C, Corona M, Cozzolino S, Fulciniti F, Cappabianca S, Rotondo A, Grassi R. Magnetic resonance imaging: a new tool for diagnosis of acute ischemic colitis? *World J Gastroenterol* 2012; **18**: 1496-1501 [PMID: 22509081 DOI: 10.3748/wjg.v18.i13.1496]
- 26 **Derikx JP**, Luyer MD, Heineman E, Buurman WA. Non-invasive markers of gut wall integrity in health and disease. *World J Gastroenterol* 2010; **16**: 5272-5279 [PMID: 21072889 DOI: 10.3748/wjg.v16.i42.5272]
- 27 **Lieberman JM**, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. *Surgery* 1997; **121**: 335-342 [PMID: 9068676 DOI: 10.1016/S0039-6060(97)90363-9]
- 28 **Kanda T**, Fujii H, Tani T, Murakami H, Suda T, Sakai Y, Ono T, Hatakeyama K. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. *Gastroenterology* 1996; **110**: 339-343 [PMID: 8566578 DOI: 10.1053/gast.1996.v110.pm8566578]
- 29 **van de Poll MC**, Derikx JP, Buurman WA, Peters WH, Roelofs HM, Wigmore SJ, Dejong CH. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. *World J Surg* 2007; **31**: 2033-2038 [PMID: 17668263 DOI: 10.1007/s00268-007-9182-4]
- 30 **Khurana S**, Corbally MT, Manning F, Armenise T, Kierce B, Kilty C. Glutathione S-transferase: a potential new marker of intestinal ischemia. *J Pediatr Surg* 2002; **37**: 1543-1548 [PMID: 12407536 DOI: 10.1053/jpsu.2002.36181]

P- Reviewers Sakata N, Keshavarzian A S- Editor Gou SX
L- Editor A E- Editor Li JY

